Screener
MeiraGTx Holdings plc MGTX License — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MeiraGTx Holdings plc in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: MeiraGTx Holdings plc’s 10-K, filed March 30, 2026.
- Filed
- Mar 30, 2026, 8:13 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-036494
| Line item | For the Years Ended December 31, 2025 | For the Years Ended December 31, 2024 |
|---|---|---|
| Revenues: | ||
| Service revenue - related party | $6,400 | $33,279 |
| License revenue | 74,991 | — |
| Total revenue | 81,391 | 33,279 |
| Operating expenses: | ||
| Cost of service revenue - related party | 4,843 | 23,791 |
| General and administrative | 52,897 | 54,216 |
| Research and development | 129,619 | 119,484 |
Item 8. Financial Statements And Supplementary DataF-
FAQ
- What is MeiraGTx Holdings plc's license — revenue?
- MeiraGTx Holdings plc (MGTX) reported license — revenue of $18.75M in Q4 2025.
- What does license — revenue mean?
- This metric represents the total revenue recognized from licensing agreements, intellectual property rights, or technology transfer arrangements within the company's gene therapy portfolio. It reflects the commercial success of monetizing proprietary research and development assets through partnerships or collaborative agreements. Tracking this revenue stream is essential for evaluating the company's ability to generate non-dilutive capital and validate the market potential of its clinical-stage pipeline.
Ask your AI about MeiraGTx Holdings plc's license — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude